학술논문
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
Document Type
Correspondence
Author
Source
In Leukemia Research April 2024 139
Subject
Language
ISSN
0145-2126